Cingulate Inc.

Healthcare · Biotechnology · United States

Last price 4.98 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 72.42M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company’s lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical...